25
algorithm at our laboratory and applied that to the thermal imaging video footage, allowing us to ensure the proper localisation of the defined facial ROI on each of the processed frames."
Results
"The present study provides two main results" Dr Merla said. "First, it showed that during the experiment the emotional distress caused by the 'breaking' of the toy lead to thermal variations in the specified facial ROI of the child. The facial thermal modulations observed in the mothers were surprisingly similar to those observed in the child. Second, facial thermal modulations of the mothers clearly correlated with corresponding modulations of their children. Thus, mother-child dyads showed a significant and situation-specific synchronicity between the autonomic reactions individually exhibited by each partner."
"Thanks to the flexibility of the FLIR SC7000 Series thermal imaging cameras physiological correlates of emotional reactions were investigated in an interactive and ecological experimental context without interfering with spontaneous behaviour", concluded Merla. "We thus proved that thermal imaging can be used to study the neurobiological foundations of social interactions, especially in ecological contexts by exploiting the contact-free nature of thermal imaging."
Reference: Ebisch SJ, Aureli T, Bafunno D, Cardone D, Romani GL, Merla A. Mother and child in synchrony: thermal facial imprints of autonomic contagion. Biological Psychology, vol. 89, p. 123-129.
http://www.sciencedirect.com/science/article/pii/S0301051111002523
Pushing Boundries in Blood Micro-Analysis
Horiba Medical, specialists in automated in vitro diagnostic systems for haematology and chemistry analysis, has launched the Microsemi CRP haematology analyser. Developed by Horiba Medical in Japan, ‘emi’ means ‘smile’ in Japanese and stands for easy to use, maintenance free and intelligent. After a highly successful release in Japan, this unique instrument is now available in Europe. This compact, easy-to-use addition to the Micros range simultaneously provides a complete blood count (CBC) and C-reactive protein (CRP) from just 18µl of blood - all in just 4 minutes.
The Microsemi CRP provides information of great clinical value enabling quicker and more accurate medical decisions to ultimately reduce hospitalisation times and patient costs. Its powerful CRP analysis allows the screening of patient samples to detect the presence of inflammation caused by bacterial infections, or other treatable inflammatory disease. Measurement is possible immediately after blood sample collection, making this analyser the ideal choice for emergency testing situations. The Microsemi CRP can also be used to assess infection and inflammatory conditions that require progressive observation. Furthermore, its micro- sampling capabilities are ideal for paediatric blood analysis, requiring just 10µL for CBC and 18µL for CBC+CRP, and can be used with capillary, as well as venous blood samples.
Comprehensive and efficient on-board software, colour touch screen, alongside fast and easy access to results adds to the Microsemi CRP’s success. Design features have created an environmentally-friendly model (using a non-cyanide reagent for haemoglobin measurement) that is incredibly compact, lightweight and quiet. The Microsemi CRP is easy to use and does not require specialised staff. All these traits make this analyser well-equipped to support changes occurring within the NHS focussed on easing the patient journey.
According to Cleve Wright, UK General Manager, Horiba Medical: “With over 2000 instruments successfully being used in Japan to date, UK clinicians can now benefit from the Microsemi CRP’s accuracy, convenience and ability to support early and rapid diagnosis of patients.”
MORE INFO. 591
ADVERTORIAL
Source BioScience Launches New MiSeq Next Generation Sequencing Service
Source BioScience , a European leader in DNA sequencing and genomic services, has extended their next generation sequencing service with the launch of the new Illumina MiSeq™ technology platform.
The launch of the MiSeq™ service establishes Source BioScience as the only commercial provider of this new technology in the UK, maintaining the Group’s position at the forefront of sequencing services as well as affirming it as the largest UK provider of Illumina sequencing.
The MiSeq™ service addresses the ‘middle ground’ between the Group’s existing Overnight Service for sequencing and the ultra high throughput HiSeq™ service, enabling access to new markets and customers for next generation sequencing.
The MiSeq™ presents significant opportunities for the Group’s Healthcare division, applying next generation sequencing to molecular diagnostics, a key component of the business.
The latest developments in cancer diagnostics and personalised treatment for patients are aimed at creating integrated genetic tests that characterise cancers at the molecular level to improve diagnosis and treatment outcome.
Dr Nick Ash, CEO of Source BioScience said: “The MiSeq™ offers rapid turnaround times for next generation sequencing, enabling scientists to access an increasing range of sequencing applications, which will attract new customers to our LifeSciences services.
“In addition, the introduction of the MiSeq™ is instrumental in realising the aims of the Technology Strategy Board grant awarded to Source BioScience in 2011.
Under this grant, Source BioScience is collaborating with a number of international partners to develop an integrated genetic test to personalise the diagnosis and treatment of cancers.”
MORE INFO. 592 MORE INFO. 593
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36
